Angela N. Giaquinto
Auto-generated profile, based on publicly available information

Angela N. Giaquinto

Cancer Surveillance Research American Cancer Society Atlanta Georgia USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2024 in CA: A Cancer Journal for Clinicians
Verified
Journal Article
Open access
RSRebecca L. Siegel
Rebecca L. Siegel
AGAngela N. Giaquinto
Angela N. Giaquinto
AJAhmedin Jemal
Ahmedin Jemal
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population‐based cancer occurrence and outcomes using incidence data collected by central cancer registries (through 2020) and mortality data collected by the National Center for Health Statistics (through 2021). In 2024, 2,001,140 new cancer cases and 611,720 cancer deaths are projected to occur in the United States. Cancer mortality continued to decline through 2021, averting over 4 million deaths since 1991 because of reductions in smoking, earlier detection for some cancers, and improved treatment options in both the adjuvant and metastatic settings. However, these gains are threatened by increasing incidence for 6 of the top 10 cancers. Incidence rates increased during 2015–2019 by 0.6%–1% annually for breast, pancreas, and uterine corpus cancers and by 2%–3% annually for prostate, liver (female), kidney, and human papillomavirus‐associated oral cancers and for melanoma. Incidence rates also increased by 1%–2% annually for cervical (ages 30–44 years) and colorectal cancers (ages <55 years) in young adults. Colorectal cancer was the fourth‐leading cause of cancer death in both men and women younger than 50 years in the late‐1990s but is now first in men and second in women. Progress is also hampered by wide persistent cancer disparities; compared to White people, mortality rates are two‐fold higher for prostate, stomach and uterine corpus cancers in Black people and for liver, stomach, and kidney cancers in Native American people. Continued national progress will require increased investment in cancer prevention and access to equitable treatment, especially among American Indian and Alaska Native and Black individuals.

16 January 2025 in CA: A Cancer Journal for Clinicians
Verified
Journal Article
Open access
RSRebecca L. Siegel
Rebecca L. Siegel
TKTyler B. Kratzer
Tyler B. Kratzer
AGAngela N. Giaquinto
Angela N. Giaquinto
HSHyuna Sung
Hyuna Sung
AJAhmedin Jemal
Ahmedin Jemal
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population‐based cancer occurrence and outcomes using incidence data collected by central cancer registries (through 2021) and mortality data collected by the National Center for Health Statistics (through 2022). In 2025, 2,041,910 new cancer cases and 618,120 cancer deaths are projected to occur in the United States. The cancer mortality rate continued to decline through 2022, averting nearly 4.5 million deaths since 1991 because of smoking reductions, earlier detection for some cancers, and improved treatment. Yet alarming disparities persist; Native American people bear the highest cancer mortality, including rates that are two to three times those in White people for kidney, liver, stomach, and cervical cancers. Similarly, Black people have two‐fold higher mortality than White people for prostate, stomach, and uterine corpus cancers. Overall cancer incidence has generally declined in men but has risen in women, narrowing the male‐to‐female rate ratio (RR) from a peak of 1.6 (95% confidence interval, 1.57–1.61) in 1992 to 1.1 (95% confidence interval, 1.12–1.12) in 2021. However, rates in women aged 50–64 years have already surpassed those in men (832.5 vs. 830.6 per 100,000), and younger women (younger than 50 years) have an 82% higher incidence rate than their male counterparts (141.1 vs. 77.4 per 100,000), up from 51% in 2002. Notably, lung cancer incidence in women surpassed that in men among people younger than 65 years in 2021 (15.7 vs. 15.4 per 100,000; RR, 0.98, p = 0.03). In summary, cancer mortality continues to decline, but future gains are threatened by rampant racial inequalities and a growing burden of disease in middle‐aged and young adults, especially women. Continued progress will require investment in cancer prevention and access to equitable treatment, especially for Native American and Black individuals.

1 October 2024 in CA: A Cancer Journal for Clinicians
Verified
Journal Article
Open access
AGAngela N. Giaquinto
Angela N. Giaquinto
HSHyuna Sung
Hyuna Sung
LNLisa A. Newman
Lisa A. Newman
RFRachel A. Freedman
Rachel A. Freedman
RSRobert A. Smith
Robert A. Smith
RSRebecca L. Siegel
Rebecca L. Siegel
This is the American Cancer Society's biennial update of statistics on breast cancer among women based on high‐quality incidence and mortality data from the National Cancer Institute and the Centers for Disease Control and Prevention. Breast cancer incidence continued an upward trend, rising by 1% annually during 2012–2021, largely confined to localized‐stage and hormone receptor‐positive disease. A steeper increase in women younger than 50 years (1.4% annually) versus 50 years and older (0.7%) overall was only significant among White women. Asian American/Pacific Islander women had the fastest increase in both age groups (2.7% and 2.5% per year, respectively); consequently, young Asian American/Pacific Islander women had the second lowest rate in 2000 (57.4 per 100,000) but the highest rate in 2021 (86.3 per 100,000) alongside White women (86.4 per 100,000), surpassing Black women (81.5 per 100,000). In contrast, the overall breast cancer death rate continuously declined during 1989–2022 by 44% overall, translating to 517,900 fewer breast cancer deaths during this time. However, not all women have experienced this progress; mortality remained unchanged since 1990 in American Indian/Alaska Native women, and Black women have 38% higher mortality than White women despite 5% lower incidence. Although the Black‐White disparity partly reflects more triple‐negative cancers, Black women have the lowest survival for every breast cancer subtype and stage except localized disease, with which they are 10% less likely to be diagnosed than White women (58% vs. 68%), highlighting disadvantages in social determinants of health. Progress against breast cancer could be accelerated by mitigating racial, ethnic, and social disparities through improved clinical trial representation and access to high‐quality screening and treatment.

10 February 2022 in CA: A Cancer Journal for Clinicians
Verified
Journal Article
Open access
PDF file
AGAngela N. Giaquinto
Angela N. Giaquinto
KMKimberly D. Miller
Kimberly D. Miller
KTKatherine Y. Tossas
Katherine Y. Tossas
RWRobert A. Winn
Robert A. Winn
AJAhmedin Jemal
Ahmedin Jemal
RSRebecca L. Siegel
Rebecca L. Siegel
African American/Black individuals have a disproportionate cancer burden, including the highest mortality and the lowest survival of any racial/ethnic group for most cancers. Every 3 years, the American Cancer Society estimates the number of new cancer cases and deaths for Black people in the United States and compiles the most recent data on cancer incidence (herein through 2018), mortality (through 2019), survival, screening, and risk factors using population‐based data from the National Cancer Institute and the Centers for Disease Control and Prevention. In 2022, there will be approximately 224,080 new cancer cases and 73,680 cancer deaths among Black people in the United States. During the most recent 5‐year period, Black men had a 6% higher incidence rate but 19% higher mortality than White men overall, including an approximately 2‐fold higher risk of death from myeloma, stomach cancer, and prostate cancer. The overall cancer mortality disparity is narrowing between Black and White men because of a steeper drop in Black men for lung and prostate cancers. However, the decline in prostate cancer mortality in Black men slowed from 5% annually during 2010 through 2014 to 1.3% during 2015 through 2019, likely reflecting the 5% annual increase in advanced‐stage diagnoses since 2012. Black women have an 8% lower incidence rate than White women but a 12% higher mortality; further, mortality rates are 2‐fold higher for endometrial cancer and 41% higher for breast cancer despite similar or lower incidence rates. The wide breast cancer disparity reflects both later stage diagnosis (57% localized stage vs 67% in White women) and lower 5‐year survival overall (82% vs 92%, respectively) and for every stage of disease (eg, 20% vs 30%, respectively, for distant stage). Breast cancer surpassed lung cancer as the leading cause of cancer death among Black women in 2019. Targeted interventions are needed to reduce stark cancer inequalities in the Black community.

20 February 2025 in CA: A Cancer Journal for Clinicians
Verified
Journal Article
Open access
ASAnatu H. Saka
Anatu H. Saka
AGAngela N. Giaquinto
Angela N. Giaquinto
LMLauren E. McCullough
Lauren E. McCullough
KTKatherine Y Tossas
Katherine Y Tossas
JSJessica Star
Jessica Star
RSRebecca L. Siegel
Rebecca L. Siegel
African American and other Black individuals (referred to as Black people in this article) have a disproportionate cancer burden, including the lowest survival of any racial or ethnic group for most cancers. Every 3 years, the American Cancer Society estimates the number of new cancer cases and deaths for Black people in the United States and compiles the most recent data on cancer incidence (herein through 2021), mortality (through 2022), survival, screening, and risk factors using population‐based data from the National Cancer Institute and the Centers for Disease Control and Prevention. In 2025, there will be approximately 248,470 new cancer cases and 73,240 cancer deaths among Black people in the United States. Black men have experienced the largest relative decline in cancer mortality from 1991 to 2022 overall (49%) and in almost every 10‐year age group, by as much as 65%–67% in the group aged 40–59 years. This progress largely reflects historical reductions in smoking initiation among Black teens, advances in treatment, and earlier detections for some cancers. Nevertheless, during the most recent 5 years, Black men had 16% higher mortality than White men despite just 4% higher incidence, and Black women had 10% higher mortality than White women despite 9% lower incidence. Larger inequalities for mortality than for incidence reflect two‐fold higher death rates for prostate, uterine corpus, and stomach cancers and for myeloma, and 40%–50% higher rates for colorectal, breast, cervical, and liver cancers. The causes of ongoing disparities are multifactorial, but largely stem from inequalities in the social determinants of health that trace back to structural racism. Increasing diversity in clinical trials, enhancing provider education, and implementing financial incentives to ensure equitable care across the cancer care continuum would help close these gaps.

7 October 2025 in Cancer
Verified
Journal Article
Open access
AGAngela N. Giaquinto
Angela N. Giaquinto
RFRachel A. Freedman
Rachel A. Freedman
LNLisa A. Newman
Lisa A. Newman
AJAhmedin Jemal
Ahmedin Jemal
RSRebecca L. Siegel
Rebecca L. Siegel
Background: Breast cancer statistics and clinical trial data largely reflect ductal carcinoma, the dominant histologic subtype, concealing important differences for invasive lobular carcinoma (ILC), the second most common subtype. Methods: Nationally representative cancer registry data from the National Cancer Institute and Centers for Disease Control and Prevention were used to report on the incidence and outcomes of ILC by age, race, and ethnicity among women in the United States. Results: In 2021 incidence of ILC was 14 per 100,000 women, which accounted for 10.6% of breast cancer diagnoses. Rates increased from 2012 through 2021 in all racial ethnic groups, ranging from 2.5% annually in American Indian/Alaska Native women to 4.4% annually in Asian American/Pacific Islander women. White women have the highest incidence overall (14.7 per 100,000), and in every age group, followed by Black women (11 per 100,000), although American Indian/Alaska Native women have the second‐highest rates among those <50. Compared to ductal carcinoma, survival for ILC is slightly higher in the first 7 years after diagnosis and similar at 10 years overall, but lower for ILC for regional‐ and distant‐stage disease, perhaps in part due to its unique metastatic pattern. Conclusion: ILC has distinctive characteristics that can contribute to delayed detection, resistance to therapy, and poorer prognosis for advanced disease. Differentiating ILC from ductal carcinoma in research and clinical trials could help identify risk factors, facilitate treatment efficacy, and lead to better understanding of metastatic mechanisms, thus improving outcomes for the increasing number of affected women.